Rohrmeier, C. and Kuehnel, T. S. (2012) Bevacizumab in therapy-refractory epistaxis. Case report of low-dose antibody therapy for hereditary hemorrhagic telangiectasia. HNO, 60 (11). pp. 1003-1006. ISSN 0017-6192,
Full text not available from this repository. (Request a copy)Abstract
We report on the submucosal injection of bevacizumab (Avastin) at a dose of 0.3 to 3.75 mg per side in a patient with hereditary hemorrhagic telangiectasia. Application of such low doses has not been described in the literature yet. Our case report shows the positive effect of low-dose bevacizumab on therapy-refractory epistaxis. No complications were caused by the bevacizumab treatment.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | ; Hereditary hemorrhagic telangiectasia; Osler disease; Bevacizumab; Epistaxis; Case report |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Hals-Nasen-Ohren-Heilkunde |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 04 May 2020 10:19 |
| Last Modified: | 04 May 2020 10:19 |
| URI: | https://pred.uni-regensburg.de/id/eprint/17874 |
Actions (login required)
 |
View Item |
